Coherus BioSciences, Inc. (CHRS)

NASDAQ: CHRS · IEX Real-Time Price · USD
2.390
-0.030 (-1.24%)
At close: Mar 28, 2024, 4:00 PM
2.380
-0.010 (-0.42%)
After-hours: Mar 28, 2024, 7:54 PM EDT

Company Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States.

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.

In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors.

Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis.

It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No.

4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012.

Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Coherus BioSciences, Inc.
Coherus BioSciences logo
Country United States
Founded 2010
IPO Date Nov 6, 2014
Industry Biotechnology
Sector Healthcare
Employees 306
CEO Dennis M. Lanfear

Contact Details

Address:
C/o Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600
Redwood City, California 94065
United States
Phone (650) 649-3530
Website coherus.com

Stock Details

Ticker Symbol CHRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001512762
CUSIP Number 19249H103
ISIN Number US19249H1032
Employer ID 27-3615821
SIC Code 2836

Key Executives

Name Position
Dennis M. Lanfear Chairman, President and Chief Executive Officer
Bryan J. McMichael Interim Chief Financial Officer, Principal Financial and Accounting Officer, SVice President-Accounting and Corporate Controller
Richard L. Hameister Chief Technical Officer
Jami Taylor Vice President of Investor Relations
Cheston Turbyfill Vice President of Communications
Scott Saywell Executive Vice President of Corporate Development
Rebecca Sunshine Chief Human Resources Officer
Michael Chen Senior Vice President of Commercial Analytics and Trade
Paul Reider Chief Commercial Officer
Dr. Theresa M. Lavallee Ph.D. Chief Development Officer and Chairman of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Mar 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 15, 2024 10-K Annual Report
Mar 13, 2024 8-K Current Report
Mar 4, 2024 8-K Current Report
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 5, 2024 8-K Current Report
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals